DOCSLIB.ORG

27Th Annual Henry Kunkel Society Meeting in Partnership with Journal of Experimental Medicine and the Rockefeller University Friday Lecture Series

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
27Th Annual Henry Kunkel Society Meeting in Partnership with Journal of Experimental Medicine and the Rockefeller University Friday Lecture Series 27th Annual Henry Kunkel Society Meeting in partnership with Journal of Experimental Medicine and the Rockefeller University Friday Lecture Series Inborn errors of immunity: from gene discovery to disease modeling and new therapies The Rockefeller University New York, NY March 21–23, 2019 Henry George Kunkel 1916–1983 enry Kunkel received his B.S. degree from Princeton and his M.D. degree from Johns Hopkins University. He arrived at The Rockefeller Institute (now HUniversity) in 1945 where he spent his entire scientific career until his death in 1983. His contributions to the field of basic and clinical immunology are legendary. He made numerous seminal observations in liver disease, rheumatic diseases and other allied disorders. He was perhaps best known for his pioneering and extensive studies on the immunoglobulins. His recognition that myeloma proteins were a model for the study of the structure of normal immunoglobulins had a global impact on investigations of the structure, function and inheritance of these molecules. The elucidation of the chain structure of gamma globulin and the recognition that immunoglobulins possessed individual antigenic specificity (idiotypes) were internationally recognized discoveries. Dr. Kunkel was the recipient of many awards and honors, including membership in the National Academy of Sciences, honorary degrees from Universities of Uppsala and Harvard, and recipient of the Lasker and Gairdner Awards and the Kovalenko Medal of the National Academy of Sciences. Henry Kunkel Society Officers President .........Jean-Laurent Casanova Secretary .........Ann Marshak-Rothstein Treasurer ...................... Eric Meffre Henry Kunkel Society Lecturers 1992 ........................Louis Kunkel 2006 ..................Ralph M. Steinman 1993 ........................... David Ho 2007 ...............Antonio Lanzavecchia 1994 ...................Benvenuto Pernis 2008 ...................... John Atkinson 1996 .....................Jeffrey Ravetch 2009 ......................Thomas Tuschl 1997 ...................... Anthony Fauci 2010 ........................Frederick Alt 1998 .....................Klaus Rajewsky 2011 .......................Mark M. Davis 1999 .......................Peter Doherty 2012 .....................Louis M. Staudt 2000 ......................Max D. Cooper 2013 ....................Daniel L. Kastner 2001 .......................Fritz Melchers 2014 ...................Shigekazu Nagata 2002 .......................Tasuku Honjo 2015 ........................Yanick Crow 2003 .........................Fred Rosen 2016 ..............Michel C. Nussenzweig 2004 ........................Diane Mathis 2017 .........................Carl Nathan 2005 ..................Charles Weissman 2018 ....................Michael Lenardo Henry Kunkel Society Members Gyorgy Abel Linda K. Bockenstedt Lucienne Chatenoud Sergio Abrignani Bjarne Bogen Talal Chatila Luciano Adorini Dusan Bogunovic† Triantafyllos Chavakis Vincent Agnello Gilles Boire Youhai Chen Rafi Ahmed† Silvia Bolland Selina Chen-Kiang Irma Airold Catherine Bollard Nicholas Chiorazzi Arne N. Akbar Stefano Bombardieri Francis V. Chisari Ivona Aksentijevich† Constantin A. Bona Carlo Chizzolini Donato Alarcon-Segovia# Jerry Boss Charles Christian Matthew Albert Marina Botto Charles Chu Mara Luisa (Marisa) Alegre Vassiliki A. Boussiotis Marcus Ramsay Clark Konstantina Alexandropoulos Jean-Pierre Bouvet Edward A. Clark Paul Allen Joseph Boyle Rachael Clark Chester A. Alper Thomas J. Braciale Menna R. Clatworthy† Marcus Altfeld Ferdinand C. Breedveld Charles Cochrane Sebastian Amigorena Samuel Breit Michel Cogné Mark Anderson Michael Brenner Richard Coico Ulf Anderson Stanley Louis Bridges Marco Colonna Paul J. Anderson Thomas Brocker Mary Ellen Conley Francesco Annuziato Eric Brown Gabriela Constantin William P. Arend Teodor-Boru Brumeanu H. Terence Cook Joseph R. Arron Yenan Bryceson David Cooper# David Artis Richard Bucala Max D. Cooper John P. Atkinson Steven Burakoff Andrew P. Cope K. Frank Austen Gerd-Rudiger Burmester Richard Cornall† Stratis Avrameas Jacinta Bustamante Joseph Craft Raffaele Badolato Joel Buxbaum Carlo M. Croce David Bahler Jill Buyon Alan Cross Jacques Banchereau Edit Buzás Mary K. Crow Vincenzo Barnaba John C. Byrd Yanick Crow Betsy Barnes Michael Cahalan Charlotte Cunningham- Franck Barrat Federico Caligaris-Cappio Rundles Craig Bassing Michael P. Cancro Riccardo Dalla-Favera Antony Basten Daniela Capello Rajendra Damle Ekkehard K. F. Bautz J. Donald Capra# Franco Dammacco Alexander Bearn# Ronald I. Carr Robert B. Darnell Timothy W. Behrens Michael C. Carroll Anne Davidson Yasmine Belkaid Robert H. Carter Mark Davis† Baruj Benacerraf# Paolo Casali Randall S. Davis J. Claude Bennett Jean-Laurent Casanova Noorbibi K. Day Jeffrey Bennett Rafael Casellas Jean-Michel Dayer Don Benson Marina Caskey Jean-Pierre de Villartay Zvi Bentwich Michael Centola Silvia Deaglio Claudia Berek Anthony Cerami Paolo Dellabona Kâre Berg Andrea Cerutti Stephen V. Desiderio Ira Berkower Ethel Cesarman Kavita Dhodapkar Robert D. Bigler, II Edward K. L. Chan Madhav V. Dhodapkar Bryce Binstadt Andrew Chan James Di Santo Richard S. Blumberg George K. Chandy Betty A. Diamond Howard Dickler Gianluca Gaidano Kevan C. Herold Guillermo Dighiero Thomas F. Gajewski Rafael Herrera-Esparza Teresa P. DiLorenzo Michael Gale, Jr Martin Herrmann Walter H. Doerfler Uri Galili Helen Heslop Peter C. Doherty Ignacio Garcia-De La Torre Ingrid Birgitta Heyman Thomas Dörner Hubert Baburaj (Bobby) Falk Hiepe Daniel Douek Gasper Adrian Hill Steven Douglas Steffen Gay Jules Hirsch# Terry William Du Clos Raif S. Geha Richard J. Hodes Anne Durandy Frédéric Geissmann V. Michael Holers George Ebers James L. German, III Steven M. Holland Dimitar G. Efremov M. Eric Gershwin Halsted R. Holman Michael Ehrenstein Paolo Ghia David Horn Götz Ehrhardt Allan Gibofsky Alan N. Houghton Klaus Eichmann Irma Gigli Thomas W. J. Huizinga Robert A. Eisenberg Gray Steven Gilkeson Mary Beth Humphrey Hani El-Gabalawy Martin John Glennie Sun Hur Keith Elkon Laurie Glimcher John Hurley# Anna Erdei Otto Goetze David A. Isenberg Doruk Erkan Leslie Gold Kimishige Ishizaka Luis R. Espinoza Raphaela Goldbach-Mansky Lionel B. Ivashkiv Paul Evans Robert A. Good# Bana Jabri Zsuzsa Fabry Christopher Goodnow Hans-Martin Jäck Andras Falus Tom Gordon Chaim Oscar Jacob Donna L. Farber Siamon Gordon Rudolf Jaenisch† A. Darise Farris Jorg J. Goronzy Israeli Jaffe C. Garrison Fathman Emil C. Gotschlich Judith A. James Douglas Thomas Fearon Susan R. S. Gottesman Roland Jonsson Ten Feizi Alice B. Gottlieb Emmanuelle Jouanguy Marc Feldmann Ellen M. Gravallese Dieter Kabelitz Gianfranco Ferraccioli Arthur Grayzel Joachim R. Kalden Manlio Ferrarini Mark Grebenau Thomas Kamradt Stefan Feske Mark I. Greene Insoo Kang Erol Fikrig Howard M. Grey Gilla Kaplan Terri Finkel Bodo Grimbacher Mariana Kaplan Alison Finnegan Luca Guidotti Mikael Karlsson Gary S. Firestein Sudhir Gupta Arthur Kaser Alain Fischer David A. Hafler Dan Kastner Vincent Fischetti Kathleen A. Haines Jonathan D. Katz Zvi Fishelson William W. Hall Michel D. Kazatchkine David E. Fisher Sophie Hambleton Jack D. Keene Kate Fitzgerald Lennart Hammarstrom Robert Kimberly Richard A. Flavell Lars Hanson Paul W. Kincade Thomas A Fleisher Morten Harboe Thomas Kindt Francesco Forconi John A. Hardin Te Piao King Ira J. Fox David M. Harlan Michael Kirschfink Marvin Fritzler John B. Harley Kai Kisand† Yang-Xin Fu Fu Jeffrey Hasday Lars Klareskog Shu Man Fu Dorian Haskard Florian Klein Herman Fudenberg# Adrian Hayday Kim L. Kline Sarah L. Gaffen Barton Haynes Glen Knight Patrick Gaffney Peter Henson Daniel M. Knowles Hon-Sum Ko Lloyd Mayer# Gustav J. V. Nossal Alisa E. Koch Maclyn McCarty# Luigi D. Notarangelo David Koffler# James McCluskey Jan Novak Frits Koning Joseph (Mike) McCune Victor Nussenzweig Dwight H. Kono A. McGehee Harvey Michel C. Nussenzweig Philippe H. A. Kourilsky Victor McKusick# James C. Oates Michael Krangel Ruslan Medzhitov Hans D. Ochs Richard Krause# Eric Meffre Lloyd Old Karsten Kretschmer Edgar Meinl Michael B. A. Oldstone James G. Krueger Fritz Melchers Eugene Oltz Vijay Kuchroo Elizabeth D. Mellins Jordan Scott Orange Dinakantha Kumararatne Henri Menard Anders Orn Steven Kunkel Miriam Merad Barbara Anne Osborne Louis Kunkel Pier Luigi Meroni C. Kirk Osterland Antonio La Cava Joan T. Merrill Mario A. Ostrowski Peter J. Lachmann Jiri Mestecky Shoichi Ozaki Robert G. Lahita Christine Metz Stephen A. Paget Antonio Lanzavecchia Dror Mevorach Savita Pahwa Sylvain Latour Isabelle Meyts Eric G. Pamer Terri Laufer Mary Ann Michelis Qiang Pan-Hammarstrom Jeffery A. Ledbetter Peter A. Miescher Sunpho Park David M. Lee Fred Miller Virginia Pascual Paul J. Lehner Eric C. B. Milner Dhavalkumar D. Patel Michael J. Lenardo Joshua Milner Andras Perl Beth Levine Toshihide Mimura Peter Perlmann Roland Liblau Seiji Minota Alessandra Pernis Peter Lipsky Pierre Miossec Benvenuto Pernis# Sergio A. Lira Chandra Mohan Erik Peterson Gary W. Litman Tom Eirik Mollnes Tri Gian Phan† Stephen Litwin Patricia K. A. Mongini Rodney Ernest Phillips Yang Liu Laurence Morel Richard Phipps Miguel Lopez-Botet Lorenzo Moretta Matthew Pickering Theresa Lu Jane Morse# Susan K. Pierce† Carrie Lucas† Bernard Moser David S. Pisetsky Pier Luigi Luigi Meroni David M. Mosser Vito Pistoia# Xiaojing Ma William A. Muller K. Michael Pollard Crystal L. Mackall Hans Muller-Eberhard# Richard M. Pope Ravinder N. Maini Kenneth Murphy Matthew Porteus† Fabio Malavasi Philip M. Murphy David N. Posnett Mark J. Mamula
Load more

Recommended publications
  • Corporate Governance
    Strategic report Governance and remuneration Financial statements Investor information Corporate Governance In this section Chairman’s Governance statement 78 The Board 80 Corporate Executive Team 83 Board architecture 85 Board roles and responsibilities 86 Board activity and principal decisions 87 Our purpose, values and culture 90 The Board’s approach to engagement 91 Board performance 94 Board Committee information 96 Our Board Committee reports 97 Section 172 statement 108 Directors’ report 109 GSK Annual Report 2020 77 Chairman’s Governance statement In last year’s Governance statement, I explained that our primary Education and focus on Science objective for 2020 was to ensure there was clarity between the Given the critical importance of strengthening the pipeline, Board and management on GSK’s execution of strategy and its the Board has benefitted from devoting a higher proportion of operational priorities. We have aligned our long-term priorities its time in understanding the science behind our strategy and of Innovation, Performance and Trust powered by culture testing its application. It is important that the Board has a and agreed on the metrics to measure delivery against them. working understanding of the key strategic themes upon The Board’s annual cycle of meetings ensures that all major which our R&D strategy is based. These themes have been components of our strategy are reviewed over the course complemented by Board R&D science thematic deep dives. of the year. Our focus was on the fundamentals of our strategy: human The COVID-19 pandemic impacted and dominated all our genetics, the immune system and AI and ML, as well as to lives for the majority of 2020.
    [Show full text]
  • Frederick Alt of Harvard University and Boston Children's Hospital
    PRESS RELEASE Frederick Alt of Harvard University and Boston Children’s Hospital Awarded 2015 Szent-Györgyi Prize for Progress in Cancer Research (Bethesda, MD – February 26, 2015) The National Foundation for Cancer Research (NFCR) announced today that Frederick Alt, Ph.D., Professor of Genetics at Harvard Medical School, Director of the Program in Cellular and Molecular Medicine at Boston Children’s Hospital, and Howard Hughes Medical Institute Investigator has been awarded the 2015 Szent-Györgyi Prize for Progress in Cancer Research. Dr. Alt’s groundbreaking work in cancer genetics over four decades has helped to shape the very roots of modern cancer research. Today, that work continues to bear fruit, profoundly impacting the approaches that doctors use to diagnose and treat cancer. NFCR’s selection committee was unanimous in its decision to recognize Dr. Alt, whose work has proved foundational to the modern understanding of cancer – not only how the lethal disease forms, but also how it can become resistant to treatment. In particular, his seminal discoveries of gene amplification and his pioneering work on molecular mechanisms of DNA damage repair have helped to usher in the era of genetically-targeted therapy and personalized medicine. “Dr. Alt has been a consistently outstanding scientist throughout his career, and this award recognizes his entire body of work,” said Dr. James Allison, Executive Director of the Immunotherapy Platform at MD Anderson Cancer Center, winner of the 2014 Szent-Györgyi Prize, and Chair of this year’s Prize Selection Committee. “The genetic processes he described are central to understanding the mechanisms that cause cancer, and have ultimately led to an entire class of targeted therapy and associated diagnos- tics that are providing benefit to countless cancer patients.” Dr.
    [Show full text]
  • Notice of Meeting for the Eighteenth Annual General Meeting (AGM) of Glaxosmithkline Plc
    GlaxoSmithKline plc Image HIV virus Notice of Annual General Meeting Thursday 3 May 2018 at 2.30pm This document is important and requires your immediate attention. If you are in any doubt as to what action you should take, you should consult your stockbroker, bank manager, solicitor, accountant or other independent professional adviser immediately. If you have sold or otherwise transferred all of your shares, please pass this document, together with the accompanying documents, to the purchaser or transferee, or to the person who arranged the sale or transfer so they can pass these documents to the person who now holds the shares. 2 29 March 2018 To the holders of the company’s Ordinary Shares and American Depositary Shares. Dear Shareholder, Annual General Meeting 2018 I am pleased to enclose the Notice of Meeting for the eighteenth Annual General Meeting (AGM) of GlaxoSmithKline plc. The AGM will be held on Thursday 3 May 2018 at 2.30pm at the QEII Centre, Broad Sanctuary, Westminster, London SW1P 3EE. If you will not be attending, you may appoint a proxy by completing and returning the enclosed proxy form. Alternatively, you may appoint a proxy electronically via www.shareview.co.uk, www.sharevote.co.uk or, if you hold your shares in CREST, via the CREST system. Notice of your appointment of a proxy should reach the company’s registrar, Equiniti, by 2.30pm on Tuesday 1 May 2018. If you hold your shares through a nominee service, please contact the nominee service provider regarding the process for appointing a proxy. Included in the business of the AGM are resolutions to receive and adopt the Directors’ Report and the Financial Statements for 2017, to approve the Annual report on remuneration for the year ended 31 December 2017 and to confirm the appointment of Deloitte LLP as the company’s auditors.
    [Show full text]
  • UNITED STATES SECURITIES and EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D INFORMATION to BE INCLUDED in STATEMENTS FI
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 240.13d-2(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 SPERO THERAPEUTICS, INC. (Name of Issuer) Common Stock, Par Value $0.001 (Title of Class of Securities) 84833T 10 3 (CUSIP Number) Victoria A. Whyte GlaxoSmithKline plc 980 Great West Road Brentford, Middlesex TW8 9GS England Telephone: +44 (0)208 047 5000 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) November 6, 2017 (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐ Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent. * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.
    [Show full text]
  • To Download a PDF of an Interview with Dr
    INTERVIEW VIEW Interview A Transformative INTER Time for Cancer Research An Interview with Dr. Laurie H. Glimcher, President and Chief Executive Offi cer, Dana-Farber Cancer Institute Over the past fi ve years, Dana-Farber has fi gure out how we can make 100 percent of had its fi ngerprints on half of the new cancer patients who have those particular tumors drugs. respond to immunotherapy. There are also When you look at the advances taking many tumors that don’t respond to immuno- place at Dana-Farber, should there be more therapy, so we have to fi gure out how to har- optimism that we’re going to achieve the ness the immune system in those patients so Laurie H. Glimcher results needed to cure cancer? that, someday, 100 percent of all patients will It’s an incredible and transformative time respond to immunotherapy. EDITORS’ NOTE Immediately prior to assum- for cancer research. The history of innovation It will take basic and translational research ing her current post, Dr. Laurie Glimcher at Dana-Farber is well-known. Sidney Farber at many different institutions, both in academia served as the Stephen and Suzanne Weiss was the fi rst person to use chemotherapy to and in the private sector, to fi gure things out. I’m Dean and Professor of Medicine at Weill cure acute leukemia, so we have a long history optimistic about success and eventually making Cornell Medical College in New York City, and of innovation. cancer a chronic disease. I hesitate to use the Provost for Medical Affairs at Cornell University.
    [Show full text]
  • Oversight Committee Board Packet
    Oversight Committee Meeting February 21, 2018 Summary Overview of the February 21, 2018, Oversight Committee Meeting This summary provides an overview of major agenda items and background on key issues for Committee consideration at the February 21, 2018, Oversight Committee meeting. CEO Report Wayne Roberts will present the CEO’s report and address issues including new personnel, available grant funds, and other topics. Mr. Roberts will also present his annual report required by Tex. Health & Safety Code § 102.260(c). Grantee Presentation – Asuragen, Inc. Dr. Gary Latham will report on Asuargen’s activities and achievements. Asuragen received a $6.8 million Commercialization/Product Development grant in 2012. Chief Compliance Officer Report Vince Burgess will report on the status of required grantee reports, financial status report reviews, desk reviews and site visits, annual compliance attestation, single audit tracking, and training. Chief Scientific Officer Report and Grant Award Recommendations Dr. James Willson will provide an update on the Academic Research Program and present the Program Integration Committee’s (PIC) award recommendations for Academic Research grant awards. CPRIT does not publicly disclose information related to the Academic Research grant applications recommended for funding until the Oversight Committee meeting. The information is available to board members through a secure electronic portal. Chief Prevention and Communications Officer Report and Grant Award Recommendations Dr. Becky Garcia will report to the Oversight Committee on the Prevention Program activities and present the PIC’s award recommendations for Prevention grant awards. She will also present the agency’s communications update, including a review of CPRIT’s 2017 Innovations Conference.
    [Show full text]
  • Immunology Club Seminar Series 2007 to Present
    Immunology Club Seminar Series 2007-Present Date Seminar Title Speaker Name Speaker Affiliation 1/4/07 Immune Control of HIV: A Perspective from Bruce Walker Harvard Medical School Studies in Africa 1/11/07 Gained in Translation: The Immunoribosome Jon Yewdell NIH Hypothesis of MHC Class I Peptide Generation 1/18/07 Oxidation stress and innate immunity Michael Carroll Harvard Medical School 1/25/07 Identification of the second thymus in mice Hans-Reimer University of Ulm Rodewald 2/1/07 The Sensing and Repair of RAG-induced DNA Barry Sleckman Washington University Double Strand Breaks by ATM School of Medicine, St. Louis 2/8/07 Body traffic -- how enteric microbiota control Jonathan Braun UCLA deployment of enteric regulatory cells 2/15/07 Linking functional stages at the NK cell Jordan Orange University of Pennsylvania cytolytic immunological synapse: insights from human genetic immunodeficiency diseases 2/22/07 Autoantibody-mediated arthritis: another view Diane Mathis Harvard Medical School of organ-targeted autoimmunity 3/1/07 Dissecting interactions between Parasites, P'ng Loke UCSF Macrophages and T cells 3/8/07 Non-histone protein lysine methylation in Alexander (Sasha) Rockefeller University immune system Tarakhovsky 3/15/07 Close Encounters: Th17 and T-reg cells Vijay Kuchroo Harvard Medical School 3/22/07 Functionally activated CD44 in T cell Mark Siegelman University of Texas activation, regulation, and trafficking Southwestern Medical Center 3/29/07 Making pancreatic lymph nodes a dangerous David Serreze Jackson Laboratory
    [Show full text]
  • Cellular and Molecular Immunology in Health and Disease
    A Symposium to Celebrate the 60th Birthday of Dr. Ranjan Sen Ranjan Sen, Ph.D., Chief, Laboratory of Molecular and Cell Biology and Immunology, National Institute on Aging CELLULAR AND MOLECULAR IMMUNOLOGY IN HEALTH AND DISEASE Frederick Alt, Ph.D. Harvard Medical School, USA Dipanjan ChowdHury, Ph.D. Harvard Medical School, USA David ScHatz, Ph.D. Date: January 30, 2016 Yale School of Medicine, USA Time: 8:30a.m. – 6:00p.m. StepHen Desiderio, M.D., Ph.D. John Hopkins Medicine, USA Place: Gerstenzang 121 Sankar GhosH, Ph.D. Brandeis University Columbia University, USA 415 SoutH Street Barbara Nikolajczyk, Ph.D. Boston University, USA WaltHam, MA 02453 StepHen Smale, Ph.D. University of California Los Angeles, USA Joel Pomerantz, Ph.D. Johns Hopkins University School of Medicine, USA Rudolf GrosscHedl, Ph.D. Max Planck Institute, Germany Batu Erman, Ph.D. Sabanci University, Turkey Christina Jamieson, Ph.D. University of California San Diego School of Medicine, USA YeHudit Bergman, Ph.D. The Hebrew University of Jerusalem, Israel Columbia University Whitehead, MIT Brandeis University National Institute of Health Ranjan Sen, Ph.D. Dr. Ranjan Sen, received his Ph.D. in chemistry from Columbia University in 1982. He made the transition to molecular biology as a postdoctoral fellow in David Baltimore's laboratory at M.I.T. and the Whitehead Institute, where he identified the transcription factor NF-κB. The NF-κB transcription factor family plays critical roles in many normal physiological processes and pathological conditions such as cancers, inflammation and autoimmune diseases. In 1987, Dr. Sen was appointed Assistant Professor in the Department of Biology and Rosenstiel Research Center at Brandeis University.
    [Show full text]
  • Fondo De Innovación Academica Programa Mecesup 2
    TERCER CONCURSO DE PROYECTOS FONDO DE INNOVACIÓN ACADEMICA PROGRAMA MECESUP 2 FORMULARIO UNICO DE PRESENTACIÓN DE PROYECTOS 2008 - UNIVERSIDADES - PARA LOS SIGUIENTES EJES Y TEMAS: EJE I DESARROLLO DE PERSONAL ACADEMICO Y PARA LA GESTIÓN. Tema 1 Personal Académico para la Investigación y el Postgrado. Tema 2 Capacidades de Gestión Académica. Tema 3 Capacitación Docente. EJE II DESARROLLO DE PROGRAMAS DE POSTGRADO NACIONALES. Tema 1 Consolidación de Programas de Doctorado Nacionales. Tema 2 Equipamiento Científico Mayor. Tema 3 Doctorados Nacionales Existentes. Tema 4 Evaluación de Impacto Género y Minorías. Tema 5 Nuevos Programas de Doctorado. Tema 6 Programas de Magíster en Gestión de Información y Gestión Tecnológica de Innovación. EJE III MEJORAMIENTO DE LOS RESULTADOS DOCENTES. Tema 1 Planes de Ajuste de Calidad en el Marco de la Acreditación de Programas de Pedagogía. Tema 2 Ideas Innovativas para un Mejor Aprendizaje. Tema 3 Evaluación de Impacto en el Aprendizaje. Eje IV MODERNIZACIÓN CURRICULAR BASADA EN RESULTADOS DE APRENDIZAJE Y COMPETENCIAS. Tema 1 Renovación Curricular del Pregrado. Tema 2 Diseño de Nuevas Iniciativas Curriculares. Tema 3 Implementación de Planes de Nivelación de Competencias Básicas para Estudiantes. TÍTULO PROYECTO (Defina un título breve que describa el sentido del proyecto y que incluya palabras claves que faciliten su búsqueda electrónica). Programa de Doctorado en Ciencias Médicas: Asegurando la formación de investigadores clínicos de excelencia. INSTITUCIÓN COORDINADORA (Señale la universidad que servirá de entidad coordinadora del proyecto y de interlocutora ante el Fondo de Innovación Académica, FIAC). Universidad de Chile INSTITUCION(ES) ASOCIADA (S) (Si el proyecto es asociado o en red, identifique a la(s) otra(s) universidad(es) participante(es)).
    [Show full text]
  • Annual General Meeting 2021 (AGM) 980 Great West Road, Brentford, Middlesex TW8 9GS on Wednesday 5 May 2021 at 2.30Pm
    Annual General Meeting 2021 (AGM) 980 Great West Road, Brentford, Middlesex TW8 9GS on Wednesday 5 May 2021 at 2.30pm Notice of Availability Electronic AGM The 2020 Annual Report and 2021 Notice of Annual General Meeting are now The AGM will be broadcast live for you to join and participate available to view and/or download in the Investors section of www.gsk.com electronically via the AGM website at https://web.lumiagm.com. Please refer to the enclosed AGM Guide or follow the instructions in the Notice of Meeting. You will need the following details to access the AGM website: Meeting ID: 140-105-232 SRN: PIN: Please note that due to COVID-19 restrictions, shareholders will unfortunately not be permitted to physically attend the meeting this year. How to vote your shares at the AGM Before completing the Proxy Form, please read the notes on appointing a proxy overleaf. You can submit your proxy instructions online (Option 1 below) or by completing and returning the Proxy Form to Equiniti (Option 2 below). In either case, your proxy instructions must be received by Equiniti by 2.30pm on Friday 30 April 2021. If you do not wish anyone other than the company or Equiniti to see the Proxy Form you may send it in an envelope to: FREEPOST RTHJ-CLLL-KBKU, Equiniti, Aspect House, Spencer Road, Lancing, BN99 8LU. No postage is required if posted within the United Kingdom. If the Proxy Form is posted outside of the United Kingdom, you should return it in an envelope, with the postage paid, to Equiniti, Aspect House, Spencer Road, Lancing, BN99 6DA.
    [Show full text]
  • 5 , 2011 Puerto Varas
    CHILEAN SOCIETY FOR CELL BIOLOGY XXV ANNUAL MEETING November, 1st – 5th, 2011 Puerto Varas SPONSORS CENTER FOR AGING AND REGENERATION (CARE) CENTRO DE ESTUDIOS MOLECULARES DE LA CELULA (CEMC) CENTRO FONDAP DE REGULACION DEL GENOMA FUNDACION CIENCIA PARA LA VIDA INSTITUTE FOR CELL DYNAMICS AND BIOTECHNOLOGY (ICDB) FUNDACION CHILENA PARA BIOLOGIA CELULAR MILLENNIUM INSTITUTE FOR FUNDAMENTAL AND APPLIED BIOLOGY (MIFAB) MILLENNIUM NUCLEUS ON IMMUNOLOGY AND IMMUNOTHERAPY (MNII) MILLENNIUM NUCLEUS IN REGENERATIVE BIOLOGY (MINREB) EXHIBITORS A. BRIL Y CIA LTDA – ALATHEIA MEDICA SA - ANDES IMPORT LTDA ARQUIMED SA – BD BIOSCIENCES – BIOSCHILE IG SA – CIENTEC SA – FERMELO SA GALENICA SA – GENESYS LTDA – GENEXPRESS – LABTEC SA LONCOTEC SA – MERCK QUIMICA DE CHILE – PERKIN ELMER CHILE ROCHE CHILE – TECNIGEN SA – TCL LTDA Chilean Society for Cell Biology – XXV Annual Meeting – November 1-5, 2011 1 INDEX CHILEAN SOCIETY FOR CELL BIOLOGY XXV ANNAUAL MEETING Program…………………………………………………………………………………………………2 Plenary Lectures…………………………………………………………………………………….....40 Symposiums……………………………………………………………………………………………44 Oral Presentations……………………………………………………………………………………..54 Poster Presentations I…………………………………………………………………………………73 Poster Presentations II……………………………………………………………………………….105 Poster Presentations III……………………………………………………………………………...137 Chilean Society for Cell Biology – XXV Annual Meeting – November 1-5, 2011 2 CHILEAN SOCIETY FOR CELL BIOLOGY XXV ANNUAL MEETING NOVEMBER, 1st-5th, 2011 PUERTO VARAS P R O G R A M Chilean Society for Cell Biology – XXV Annual
    [Show full text]
  • The Unfolded Protein Response in Breast Cancer
    cancers Review The Unfolded Protein Response in Breast Cancer Eoghan P. McGrath 1,2 , Susan E. Logue 1,2 , Katarzyna Mnich 1,2 , Shane Deegan 1,2, Richard Jäger 3 , Adrienne M. Gorman 1,2 and Afshin Samali 1,2,* 1 Apoptosis Research Centre, National University of Ireland (NUI), Galway, University Road, Galway, H91 TK33 Galway, Ireland; [email protected] (E.P.M.); [email protected] (S.E.L.); [email protected] (K.M.); [email protected] (S.D.); [email protected] (A.M.G.) 2 School of Natural Sciences, NUI Galway, University Road, H91 TK33 Galway, Ireland 3 Department of Natural Sciences, Bonn-Rhein-Sieg University of Applied Sciences, 53359 Rheinbach, Germany; [email protected] * Correspondence: [email protected]; Tel.: +353-91-492440 Received: 3 August 2018; Accepted: 18 September 2018; Published: 21 September 2018 Abstract: In 2018, in the US alone, it is estimated that 268,670 people will be diagnosed with breast cancer, and that 41,400 will die from it. Since breast cancers often become resistant to therapies, and certain breast cancers lack therapeutic targets, new approaches are urgently required. A cell-stress response pathway, the unfolded protein response (UPR), has emerged as a promising target for the development of novel breast cancer treatments. This pathway is activated in response to a disturbance in endoplasmic reticulum (ER) homeostasis but has diverse physiological and disease-specific functions. In breast cancer, UPR signalling promotes a malignant phenotype and can confer tumours with resistance to widely used therapies. Here, we review several roles for UPR signalling in breast cancer, highlighting UPR-mediated therapy resistance and the potential for targeting the UPR alone or in combination with existing therapies.
    [Show full text]